-
As of December 2025, the WHO has issued its first guidelines recommending long-term use of GLP-1 medications like Wegovy and Mounjaro for obesity treatment, recognizing obesity as a chronic disease. The US government has negotiated significant price cuts for these drugs, expanding Medicare and Medicaid coverage to more patients. However, concerns remain about drug accessibility, side effects, and weight regain after stopping treatment.
-
Novo Nordisk's trials of the drug Rybelsus, containing semaglutide, did not meet their primary goal of delaying cognitive decline in early Alzheimer's patients. While some biological processes improved, the studies showed no effect on cognition. Shares fell sharply amid disappointment, though the drug remains beneficial for diabetes and obesity.
-
The FDA has approved a daily oral version of Wegovy, a popular weight-loss drug, making it the first of its kind. The pill, containing 25mg of semaglutide, is nearly as effective as the injectable form, potentially broadening access and reducing costs for millions with obesity and diabetes.
-
As of January 2026, weight-loss drugs like Wegovy and Mounjaro deliver significant initial weight loss, with new approvals expanding dosing options. However, research shows most patients regain lost weight within 20 months after stopping treatment. High costs, side effects, and misconceptions about long-term use contribute to discontinuation. Experts emphasize the need for ongoing lifestyle support and gradual dose reduction to sustain benefits.